Hepatitis B Virus Genotypes among Egyptian Patients

Protocol of thesis
Submitted for partial fulfillment of Master Degree
In Clinical and Chemical Pathology

By

Dina Mahmoud El-Sayed
M.B., B.Ch.
Cairo University

Supervised by

Professor/Aisha Yassin Abdel Ghaffar
Professor of Clinical and Chemical Pathology
Faculty of Medicine-Ain Shams University

Professor/Salwa Ibrahim Bakr
Professor of Clinical and Chemical Pathology
Faculty of Medicine-Ain Shams University

Doctor/Dina El-Sayed El-Shennawy
Lecturer of Clinical and Chemical Pathology
Faculty of Medicine-Ain Shams University

Faculty of Medicine
Ain Shams University
2010
To My Mother,
To my beloved, caring and understanding husband.
First of all, Thanks to Allah

I would like to express my deepest thanks, gratitude and profound respect to my honored Prof. Aisha Yassin Abdel Ghaffar, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her meticulous supervision. I consider myself fortunate to work under her supervision. Her constant encouragement and constructive guidance were of paramount importance for the initiation, progress and completion of this work.

I would like to extend my thanks to Prof. Salwa Ibrahim Bakr, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her active participation in this work. She really did her best to get this work fulfilled.

Also I would like to thank Dr. Dina El-Sayed El-Shennawy, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, who offered me a lot of guidance, continuous encouragement and advice while supervising every step in this work.

I would also like to express my great gratitude to Prof. Hatem Mahmoud El-Seba‘ee, Professor of Medical Biochemistry, Faculty of Medicine, Al-Monofeya University and Dr. Ashraf Yossef El-Fert, Lecturer of Clinical Biochemistry, Faculty of Medicine, Al-Monofeya University, for their indispensable effort and help in the practical part of this work.
# List of Contents

**Introduction** ........................................................................................................ 1

**Aim of the work** ................................................................................................... 3

**Hepatitis B virus** ................................................................................................ 4
  - HBV structure and genome ............................................................................. 4
  - HBV life cycle .................................................................................................. 7
  - HBV serotypes, genotypes and mutants ...................................................... 12
  - Immunopathogenesis of HBV infection ....................................................... 13
  - Natural history of HBV infection ................................................................. 29
  - Epidemiology of HBV infection .................................................................. 35
  - Clinical feature of HBV infection ................................................................. 37
  - Diagnosis of HBV infection .......................................................................... 39
  - Follow up of HBV infection ......................................................................... 42
  - Prevention of HBV infection ........................................................................ 42

**HBV genotypes** .................................................................................................. 44
  - Geographic distribution of HVB genotypes ............................................... 45
  - HBV genotype and disease progression ...................................................... 47
  - HBV genotype and HBcAg seroconversion and viral load .......................... 49
  - HBV genotype and anti-viral therapy ......................................................... 50
  - HBV genotype and liver transplantation .................................................... 53
  - Determination of HBV genotype ................................................................. 54

**Subjects and Methods** ..................................................................................... 60

**Results** ............................................................................................................... 69

**Discussion** ......................................................................................................... 75

**Recommendations** ............................................................................................ 79

**Summary** ........................................................................................................... 80

**References** ......................................................................................................... 82

**Arabic Summary** .................................................................................................
List of Tables

Table 1: Characteristics of chronic hepatitis B at different stages. ................................................................. 35
Table 2: Serological and virological profiles in patients with HBV infection.................................................... 41
Table 3: Advantages and disadvantages of different HBV genotyping methods. .............................................. 58
Table 4: Statistical comparison between chronic hepatitis B Egyptian patients with genotype B and D as regard age, level of ALT and AST, and viremia level.......................................................... 71
Table 5: Statistical comparison between chronic hepatitis B Egyptian patients with genotype B and D according to gender.......................................................... 72
Table 6: Correlation between studied parameters.............. 73
# List of Figures

**Figure 1:** Schematic structure of the HBV particle and subviral particles .......................................................... 5

**Figure 2:** The genome organisation of HBV ....................... 7

**Figure 3:** Hepatitis B virus replication ................................. 10

**Figure 4:** Coordinate activation of innate and adaptive response is necessary for HBV control .................. 19

**Figure 5:** Platelets facilitate the accumulation of CTLs in the infected liver .......................................................... 22

**Figure 6:** Correlation of T-cell defects with virus replication levels ................................................................. 25

**Figure 7:** HBV-specific T-cell tolerance ............................... 26

**Figure 8:** Schematic figure of how the B7-H1/PD-1 pathway may mediate the exhaustion of virus-specific T cells in chronic HBV infection ........... 29

**Figure 9:** Natural history of HBV infection .......................... 30

**Figure 10:** The progression from acute to chronic HBV infection .................................................................. 40

**Figure 11:** Geographical distribution of HBV genotypes .......... 47

**Figure 12:** RFLP pattern of the products of DNA fragment of the S region (Genotype B) ......................... 66

**Figure 13:** RFLP pattern of the products of DNA fragment of the S region (Genotype D) ............... 67

**Figure 14:** Percentages of HBV genotypes in chronic hepatitis B Egyptian patients ............................ 69

**Figure 15:** Comparison between cases with genotype B or D according to gender .............................................. 72

**Figure 16:** Scatter diagram showing the relation between age and AST ............................................................ 73

**Figure 17:** Scatter diagram showing the relation between age and ALT .............................................................. 74
List of Abbreviation

**AFP:** Alpha-fetoprotein  
**ALT:** Alanine aminotransferase  
**Anti-HBc:** Anti hepatitis B core antibody  
**Anti-HBs:** Anti hepatitis B surface antibody  
**APCs:** Antigen-presenting cells  
**BCR:** B cell receptor  
**ccc DNA:** Covalently closed circular DNA  
**CD:** Cluster of differentiation  
**CTL:** Cytotoxic T lymphocytes  
**DCs:** Denderitic cells  
**Fas L:** Fas ligand  
**GM-CSF:** Granulocyte-macrophage colony-stimulating factor  
**G145R:** Glycine to Arginine substitution at codon 145  
**HBcAg:** Hepatitis B core antigen  
**HBeAg:** Hepatitis B envelope antigen  
**HBsAg:** Hepatitis B surface antigen  
**HBV:** Hepatitis B virus  
**HCC:** Hepatocellular carcinoma  
**ICU:** Intensive care unit  
**IFN-α/β/γ:** Interferons alpha/beta/gamma  
**Ig:** Immunoglobulin  
**IHL:** Intra-hepatic lymphocytes
IL : Interleukin
INNO-LIPA: Innogenetics line probe assay
IRF3: Interferon regulatory factor 3
ISGs: IFN-stimulated genes
L protein: Large protein
M protein: Medium protein
MCA: Melting curve analysis
M-CSF: Macrophage colony-stimulating factor
MDA5: Melanoma differentiation associated gene 5
mDCs: Myeloid dendritic cells
MHC: Major histocompatibility complex
MIP-1α: Macrophage-inflammatory protein-1α
mRNA: Messenger RNA
NF-κβ: Nuclear factor-κβ
NK: Natural killer
NKT: Natural killer T
OBI: Occult HBV infection
ORF: Open reading frame
P: Polymerase
PD: Programmed death
pDC: Plasmacytoid dendritic cells
PD-L1: Programmed death-ligand 1
pg RNA: Pre-genomic RNA
PRRs: Pattern recognition receptors
RFLP: Restriction fragment length polymorphism
<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIG-I</td>
<td>Retinoic acid-inducible gene I</td>
</tr>
<tr>
<td>S protein</td>
<td>Small protein</td>
</tr>
<tr>
<td>SOI</td>
<td>Secondary occult infection</td>
</tr>
<tr>
<td>SVP</td>
<td>Subviral particles</td>
</tr>
<tr>
<td>Th1</td>
<td>T helper-1</td>
</tr>
<tr>
<td>Th2</td>
<td>T helper-2</td>
</tr>
<tr>
<td>TLRs</td>
<td>Toll-like receptors</td>
</tr>
<tr>
<td>TRAIL</td>
<td>TNF-related apoptosis-inducing ligand</td>
</tr>
</tbody>
</table>
INTRODUCTION

Hepatitis B virus (HBV) is very common worldwide. It is characterized by causing hepatitis B. However, it can also lead to cirrhosis and hepatocellular carcinoma (HCC). It has also been suggested that it may increase the risk of pancreatic cancer (Hassan et al., 2008). Chronic infection with HBV is a common cause of death associated with liver failure, cirrhosis, and liver cancer. Worldwide, approximately 350 million persons have chronic HBV infection, and an estimated 620,000 persons die annually from HBV-related liver disease (Goldstein et al., 2005).

A classification reflecting the phylogenetic origin of the virus isolates was proposed dividing HBV into eight genotypes designated A to H. These genotypes were differentiated by a sequence divergence in the entire genome exceeding 8%. While, subgenotypes have been described which differ by at least 4% (Norder et al., 2004). The genotypes show a distinct geographical distribution between, and even within, regions and are proving to be an invaluable tool in tracing the molecular evolution and patterns and modes of spread of HBV. Structural and functional differences between genotypes can influence the severity, course and likelihood of complications, hepatitis B e antigen (HBeAg) seroconversion as well as response to treatment of HBV infection and possibly vaccination against the virus (Chu et al., 2002).

As of today, HBV genotypes remain significant mostly from the research point of view. However, there is growing evidence from research being conducted around the globe that
the day when HBV genotypes will become as important clinically as hepatitis C virus genotypes may not be too far away (Mahtab et al., 2008).
Aim of The Work

The aim of this work is to detect the predominant genotype(s) of HBV among the Egyptian chronic hepatitis B patients and its relation to the disease state.
HEPATITIS B VIRUS INFECTION

A) HBV Structure and Genome:

The HBV is classified as the type species of the Orthohepadnavirus (Hunt, 2007). The genus is classified as part of the Hepadnaviridae (hepatotropic DNA viruses) family which have not been assigned to a viral order (Mason et al., 2008).

The infectious HBV virion (also known Dane particle) is a spherical particle, 42 nm in diameter. The virion contains the nucleocapsid which consists of the circular partially double-stranded genomic DNA covalently linked to the viral reverse-transcriptase. This nucleocapsid is surrounded by a lipid bilayer in which the three envelope proteins [small (S), medium (M) and large (L)] are anchored as transmembrane proteins playing a major role in HBV morphogenesis and infectivity (Bruss, 2007). The HBV surface proteins are not only incorporated into the virion envelope but also bud in an empty and non-infectious subviral particles (SVP). They consist of an envelope glycoprotein and host derived lipids. The SVP conformation is organized as an octahedral sphere about 20 nm in diameter or as a filament with the same diameter but with variable length (Gilbert et al., 2005) (Fig.1). The SVPs reach a 10,000 fold higher concentration than virions in the serum. The precise biological significance of this massive overproduction of such SVP is unknown; however, it has been speculated that they
serve as decoys for host’s immune system (Zekry and Mchutchison, 2007).

Fig. 1: Schematic Structure of the HBV Particle and Subviral Particles. The envelope is formed by the three viral surface proteins LHBs, MHBs and SHBs that surround the viral nucleocapsid. The core protein (HBcAg) forms the nucleocapsid that harbors the partially double-stranded circular DNA genome that is covalently linked to the viral polymerase. In the serum of HBV-positive patients, large amounts of non-infectious subviral particles in the form of filaments or spheres are found; these are composed of the viral surface proteins, but lack the viral nucleic acid (Schädler and Hildt, 2009).

The genome of HBV is made of circular DNA, but it is unusual because the DNA is not fully double-stranded. The 5' end of the full length strand (minus strand) is linked to the viral DNA polymerase, while the 5' end of the short length strand (plus strand) is linked with short piece of capped RNA. The